3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Hypogonadism
3
Testicular Neoplasms
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Multiple Endocrine Neoplasia Type 1
1
Klinefelter Syndrome
1
Infertility
1
Fatigue Syndrome, Chronic
1
Eunuchism
1
Carcinoma, Renal Cell
1
Interventions
Nivolumab
74
Sunitinib
73
pembrolizumab
49
Everolimus
39
Sorafenib
36
Bevacizumab
36
Axitinib
36
cabozantinib
35
Radiosurgery
33
Ipilimumab
33
pazopanib
32
Magnetic Resonance Spectroscopy
27
Interleukin-2
27
aldesleukin
23
Specimen Handling
22
Cyclophosphamide
21
lenvatinib
20
fludarabine phosphate
17
Radiotherapy
16
Interferon-alpha
15
Peripheral Blood Stem Cell Transplantation
14
Gemcitabine
14
Biopsy
14
temsirolimus
13
Nephrectomy
13
durvalumab
11
Immunohistochemistry
11
CTLA-4 Antigen
11
Blood Specimen Collection
11
Capecitabine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Renal Cell
×
testosterone undecanoate
×
Clear all
NCT03379012
2019-10-22
FARETES
Kidney Cancer Research Bureau
Phase 2
Completed
60 enrolled